• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medication are ineffective. A customized treatment may be the answer.

Cue is an intervention platform for digital devices that converts passively collected smartphone sensor data into personalized micro-interventions that improve mental health. We analyzed the best-fitting personalized ML models to each person, using Shapley values to discover their features and predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

depression pharmacological Treatment is among the leading causes of mental illness.1 However, only about half of those suffering from the condition receive treatment1. To improve outcomes, healthcare professionals must be able to recognize and treat patients who have the highest probability of responding to specific treatments.

A customized depression treatment is one method to achieve this. Using mobile phone sensors as well as an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from which treatments. Two grants were awarded that total over $10 million, they will use these techniques to determine biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research done to the present has been focused on clinical and sociodemographic characteristics. These include demographic factors like age, sex and education, clinical characteristics including symptoms severity and comorbidities and biological markers such as neuroimaging and genetic variation.

While many of these aspects can be predicted from the data in medical records, few studies have employed longitudinal data to explore the causes of mood among individuals. Few studies also take into consideration the fact that moods can differ significantly between individuals. Therefore, it is crucial to devise methods that allow for the identification and quantification of individual differences in mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to recognize patterns of behaviour and emotions that are unique to each person.

In addition to these methods, the team also developed a machine-learning algorithm that models the dynamic factors that determine a person's depressed mood. The algorithm combines these individual differences into a unique "digital phenotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated severity scale for symptom severity. However, the correlation was weak (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is the leading cause of disability around the world, but it is often misdiagnosed and untreated2. Depressive disorders are often not treated due to the stigma that surrounds them and the absence of effective treatments.

To allow for individualized treatment, identifying patterns that can predict symptoms is essential. However, current prediction methods depend on the clinical interview which is unreliable and only detects a tiny number of features associated with depression treatment psychology.2

Machine learning is used to blend continuous digital behavioral phenotypes captured through smartphone sensors and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) along with other indicators of severity of symptoms has the potential to increase the accuracy of diagnostics and the effectiveness of treatment for depression during pregnancy treatment. These digital phenotypes capture a large number of distinct behaviors and activities that are difficult to document through interviews, and allow for continuous and high-resolution measurements.

The study included University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. participating in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical treatment according to the severity of their depression. Patients who scored high on the CAT-DI scale of 35 or 65 were given online support with a coach and those with scores of 75 patients were referred to psychotherapy in person.

At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial characteristics. These included sex, age education, work, and financial situation; whether they were divorced, partnered or single; the frequency of suicidal ideation, intent or attempts; and the frequency at the frequency they consumed alcohol. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale of 0-100. The CAT-DI tests were conducted every other week for participants that received online support, and weekly for those receiving in-person support.

Predictors of the Reaction to Treatment

Research is focused on individualized depression treatment. Many studies are focused on identifying predictors, which will aid clinicians in identifying the most effective medications to treat each individual. In particular, pharmacogenetics identifies genetic variants that determine how long does depression treatment last the body's metabolism reacts to antidepressants. This lets doctors choose the medications that are most likely to work for each patient, while minimizing the time and effort needed for trial-and-error treatments and avoiding any side consequences.

Another promising method is to construct models for prediction using multiple data sources, including clinical information and neural imaging data. These models can be used to determine the variables that are most predictive of a particular outcome, such as whether a drug will help with symptoms or mood. These models can be used to determine the patient's response to treatment, allowing doctors to maximize the effectiveness of their treatment.

A new generation uses machine learning techniques like the supervised and classification algorithms, regularized logistic regression and tree-based techniques to combine the effects of multiple variables and improve predictive accuracy. These models have shown to be useful in forecasting treatment outcomes, such as the response to antidepressants. These approaches are becoming more popular in psychiatry and could become the norm in the future clinical practice.

Research into depression's underlying mechanisms continues, in addition to predictive models based on ML. Recent findings suggest that depression is connected to dysfunctions in specific neural networks. This theory suggests that individualized depression treatment will be focused on therapies that target these circuits in order to restore normal functioning.

Internet-based interventions are an option to accomplish this. They can provide an individualized and tailored experience for patients. A study showed that a web-based program improved symptoms and provided a better quality life for MDD patients. Furthermore, a randomized controlled study of a customized treatment for depression demonstrated sustained improvement and reduced side effects in a significant number of participants.

Predictors of adverse effects

In the treatment of depression, one of the most difficult aspects is predicting and identifying the antidepressant that will cause minimal or zero negative side effects. Many patients are prescribed a variety of medications before settling on a treatment that is effective and tolerated. Pharmacogenetics provides an exciting new method for an efficient and targeted approach to choosing antidepressant medications.

There are many variables that can be used to determine which antidepressant should be prescribed, including gene variations, phenotypes of the patient like gender or ethnicity and co-morbidities. However finding the most reliable and reliable factors that can predict the effectiveness of a particular treatment will probably require randomized controlled trials of considerably larger samples than those typically enrolled in clinical trials. This is because the detection of moderators or interaction effects could be more difficult in trials that only take into account a single episode of treatment per patient instead of multiple episodes of treatment over a period of time.

Furthermore to that, predicting a patient's reaction will likely require information on the severity of symptoms, comorbidities and the patient's own experience of tolerability and effectiveness. At present, only a handful of easily identifiable sociodemographic variables and clinical variables appear to be reliably related to response to MDD. These include age, gender and race/ethnicity as well as BMI, SES and the presence of alexithymia.

There are many challenges to overcome when it comes to the use of pharmacogenetics for depression treatment. First, it is important to be able to comprehend and understand the definition of the genetic mechanisms that cause depression, as well as an accurate definition of an accurate indicator of the response to treatment. Additionally, ethical issues such as privacy and the appropriate use of personal genetic information must be carefully considered. In the long term pharmacogenetics can be a way to lessen the stigma associated with mental health treatment and improve the treatment outcomes for patients with depression. However, as with all approaches to psychiatry, careful consideration and implementation is essential. For now, it is best to offer patients an array of depression medications that work and encourage patients to openly talk with their doctors.